Disposition and clinical efficacy of methotrexate in patients with rheumatoid arthritis following weekly, low, intramuscular dosing: A pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 7, 1997, Pages 434-445

  Desoky, Ehab E L ^a   Khalifa, Mohammed M A ^b   Mahmoud, Jehan A ^c   Ebraheem, Salwa A T ^b   Klotz, Ulrich ^d  

^a Assiut University Faculty of Medicine   (Egypt)

^b Minia University   (Egypt)

^c MINIA UNIVERSITY HOSPITAL   (Egypt)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Methotrexate; Pharmacodynamics; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

INDOMETACIN; METHOTREXATE; PIROXICAM;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; JOINT FUNCTION; MALE; MORNING STIFFNESS; NAUSEA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0030825710     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80034-3     Document Type: Article

References (24)

1. Bannwarth B, Labat L, Monde Y, et al. Methotrexate in rheumatoid arthritis. An update. Drugs. 1994;47:25-50.
2. Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30:194-210.
3. Dozier N, Brumbaugh B. Methotrexate. In: Taylor WJ, Caviness MHD, eds. A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Irvine, Tex.; Abbott Laboratories; 1986.
4. Herman RA, Veng-Pedersen P, Hoffman J, et al. Pharmacokinetics of low dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989;78:165-171.
5. Seideman P, Beck O, Eksborg S, et al. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993;35:409-412.
6. Arnett FC, Edworthy SM, Block DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
7. Combe B, Edno L, Lafforgue P, et al. Total and free methotrexate pharmacokinetics with and without piroxicam in rheumatoid arthritis patients. Br J Rheumatol. 1995;34:421-428.
8. Steinbroker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140:659-662.
9. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968;37:393-406.
10. Williams HJ, Ward JR, Reading JC, et al. Comparison of auranofin, methotrexate and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum. 1992;35:259-269.
11. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A metaanalysis of published clinical trials. Arthritis Rheum. 1992;35:1117-1124.
12. Campbell MA, Perrier DG, Dorr RT, et al. Methotrexate: Bioavailability and pharmacokinetics. Cancer Treat Rep. 1985;69:833-838.
13. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol. 1993;20:263-267.
14. Sinett MJ, Grof GD, Raddatz DA, et al. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1989;16:745-748.
15. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res. 1983;43:2342-2345.
16. Schroder H, Clausen N, Ostergaard E, et al. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. Cancer Chemother Pharmacol. 1986;16:190-193.
17. Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 1988;21:145-149.
18. Schroder H. In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Dan Med Bull. 1990;37:22-40.
19. Rooney TW, Furst DE. Methotrexate. In: McCarty DJ, Koopman WJ, eds. Arthritis and Allied Conditions. A Textbook of Rheumatology. Vol. 1. Philadelphia: Lea & Febiger; 1993:621-636.
20. Monjanel S, Rigault JP, Cano JP, et al. High dose methotrexate: Preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol. 1979;3:189-196.
21. Schilsky RL. Clinical pharmacology of methotrexate. In: Ames, et al, eds. Pharmacokinetics of Anticancer Agents in Humans. Princeton: Elsevier; 1983:187-205.
22. Bressole F, Bologna C, Gomeni R, et al. Bayesian approach to estimate methotrexate pharmacokinetics in rheumatoid arthritis patients [abstract, A-399]. Proceedings of the 1st Congress-European Association for Clinical Pharmacology and Therapeutics; September 27-30, 1995: Paris, France: Journal de pharmacologie clinique et de therapeutique, S7-S170.
23. Weinblatt ME, Maier AL. Long term experience with low dose weekly methotrexate in rheumatoid arthritis. J Rheumatol. 1990;17(Suppl 22):33-38.
24. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. NEJM. 1994;330:1368-1375.